Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 4/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754371 | 1.00 | TRPV1 (0.39) | TRPV1SMOUSP30WNT3ACD274 | |
| SCHEMBL16754404 | 0.89 | WNT3A (0.34) | USP30WNT3AIRAK4DYRK1A | |
| SCHEMBL16754683 | 0.88 | MAPT (0.38) | TRPV1SMOUSP30WNT3AMAPT | |
| SCHEMBL17618410 | 0.86 | TRPV1 (0.42) | TRPV1SMOHSD17B10 | |
| SCHEMBL17618509 | 0.85 | WNT3A (0.41) | TRPV1WNT3ADYRK1A | |
| SCHEMBL16754671 | 0.85 | HRH3 (0.38) | USP30WNT3AHSD17B10 | |
| SCHEMBL16754667 | 0.84 | USP30 (0.36) | USP30WNT3AIRAK4 | |
| SCHEMBL16775778 | 0.84 | EGFR (0.35) | TRPV1SMOHSD17B10SMPD3 | |
| SCHEMBL16754615 | 0.83 | L3MBTL1 (0.35) | USP30WNT3AHSD17B10IRAK4 | |
| SCHEMBL17778384 | 0.83 | L3MBTL1 (0.35) | USP30WNT3AHSD17B10IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TRPV1 4032/4885SMO 3993/4885USP30 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.